The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs

ISSN: 2212-6988 (Online)
ISSN: 2212-697X (Print)


Volume 1, 2 Issues, 2014






Clinical Cancer Drugs

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Yuval Shaked
Department of Molecular Pharmacology Rappaport Faculty of Medicine, Technion - Israel Institute of Technology
Haifa
Israel


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs

Author(s): Antonello Di Paolo, Guido Bocci and Romano Danesi

Affiliation: Department of Clinical and Exprimental Medicine, Via Roma 55, 56126 Pisa – Italy.

Abstract

In the present review we report the preclinical development of paclitaxel-based combination treatment with antiangiogenic drugs and their translation into clinical practice. A particular attention is paid to the mechanisms by which an interaction between paclitaxel and antiangiogenic drugs may be advocated. In mid ‘90s, the discovery of the antiangiogenic properties of paclitaxel has widened the possible uses of the drug for the treatment of solid tumors. In fact, paclitaxel is able to negatively modulate vascular endothelial growth factor (VEGF) and angiopoietin-1 expression, whereas the drug may induce an increased expression of the antiangiogenic endogenous modulator thrombospondin-1. On the basis of these discoveries, several promising antiangiogenic treatments have been identified in preclinical models, in which paclitaxel has been administered together with direct antiangiogenic drugs (i.e., bevacizumab and vandetanib). In other cases, the paclitaxel-based combination included inhibitors of those mediators whose activity is associated with and supports neovessel formation, such as matrix metalloproteinases, cyclooxygenase-2 and endothelin-1. The synergistic cytotoxic effect of combined treatments may depend on the capability of paclitaxel to inhibit both tissue invasion by tumors (i.e., antagonizing matrix metallo-proteinase activity) and secretion of pro-angiogenic mediators (i.e., VEGF) through an antagonistic effect of the taxane against endothelin-1/endothelin A receptor. Some of these combination treatments have not yet (or will not) reach clinical studies and the therapeutic armamentarium, despite the promising results achieved in preclinical models. However, they may play a role as proof-of-concept in the growing knowledge and interest in the mechanism by which we can modulate or halt angiogenic processes driven by tumors.

Keywords: Angiogenesis, angiopoietin-1, antiangiogenic drugs, bevacizumab, cediranib, celecoxib, cetuximab, gefitinib, lapatinib, matrix metalloproteinases, monoclonal antibodies, paclitaxel, preclinical studies, receptor tyrosine-kinases, sorafenib, thrombospondin-1, TNP-470, trastuzumab, vandetanib, vascular endothelial growth factor.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 1
Issue Number: 2
First Page: 100
Last Page: 115
Page Count: 16
DOI: 10.2174/2212697X01666131218234741
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science